Article

Segment 3 - Provider Buy-in and Clinical Pathway Development

Dr Yu said that it is crucial for providers' voices to be heard in pathway development.

Dr Yu said that it is crucial for providers’ voices to be heard in pathway development.

“If you’re going to be successful, you need to have buy-in. If you need to have buy-in, you need to have people believe that it’s a transparent process of pathways development that they respect and feel that they had a voice in,” he explained.

He detailed how a healthcare setting can also impact pathway development, and the role that published medical literature has on the real-world setting practice. The actual experience of implementing pathways and patient behavior need to be closely monitored. There should also be feedback loops that include physicians.

Dr Tischler agreed, saying that provider buy-in is necessary. He said that for authentic buy-in, one cannot force a caregiver to act or practice in a certain way.

Related Videos
Debra Patt, MD, PhD, MBA, MPH
Clayton Irvine, PharmD, MBA, MS.
Debra Patt, MD, PhD, MBA, MPH
Carrie Kozlowski, OT, MBA, Upfront Healthcare
Debra Patt, MD, PhD, MBA, MPH
Chelsee Jensen, PharmD, BCPS.
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Sandra Cuellar, PharmD
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo